Tandem Bio and Therakind Ltd Enter Agreement to Advance New Candidates for Antimicrobial Drug Resistance
BOSTON, MA / ACCESSWIRE / January 3, 2024 / Tandem Biotherapeutics, a pioneering biotech firm based in Boston, and Therakind Ltd, a UK-based pharmaceutical company specializing in innovative drug formulations, are proud to announce their intellectual property licensing agreement.
This alliance is set to propel the significant discoveries of Dr. Gramignoli, Associate Professor of Laboratory Medicine, at Karolinska Institutet and the Head of Cell Therapy Research at Tandem Biotherapeutics, and the bacteriologist, Dr. Federico Iovino, Associate Professor of Neuroscience, Karolinska Institutet.
Louise Rawcliffe, Program Director of Therakind Ltd, commented, "Our vision for a new therapy to combat antibiotic-resistant bacteria carries significant implications for human health. We are committed to transforming these early-stage discoveries into viable solutions that benefit patients across the globe."
Dr Christineh Sarkissian, CSO of Tandem, added, "This agreement is a testament to Tandem's innovative discovery platform and reinforces our dedication to adding value by licensing promising discoveries." "Tandem's core mission, focusing on cell therapy for congenital organ defects, continues to guide our strategic focus", explains David Paolella, Tandem's CEO.
For additional details on this exciting collaboration or to speak with a company representative, please reach out to:
insights@tandembio.com or bd@therakind.com
About Tandem Biotherapeutics
Tandem Biotherapeutics specializes in the development of cell therapy treatments for Inborn Errors of Metabolism (IEMs) in Boston. Utilizing regenerative medicine techniques, Tandem strives to create cutting-edge cellular product treatments.
About Therakind Ltd
Therakind, a pharmaceutical company based in London (UK), is focused on developing niche medicines in difficult-to-treat patient groups including children, the elderly, and those suffering from chronic illness. Children and the elderly are two population groups with a higher risk for infections due to their non-fully developed or weaker, respectively, immune systems.
Contact Information:
Company: Tandem Biotherapeutics
Address: Boston, MA
Email: insights@tandembio.com
Website: www.tandembio.com
SOURCE: Tandem
View the original press release on accesswire.com
ACCESSWIRE
